Cochrane · systematic review · CD008655
The impact of biological interventions for ulcerative colitis on health‐related quality of life
LeBlanc, K, Mosli, MH, Parker, CE, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
20
current version
GRADE rated
20
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 5%Low 1 · 5%Moderate 14 · 70%High 4 · 20%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Interferon‐B‐1a versus placebo
Population: patients with active ulcerative colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Improved IBDQ at week 8 Interferon‐B‐1a vs placebo | RR 1.14 [0.8, 1.61] | 1 study · 194 participants | Moderate Downgraded: imprecision |
Rituximab versus placebo
Population: patients with active ulcerative colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
IBDQ at week 12 Rituximab vs placebo | no estimate extracted | 1 study · 22 participants | Very low Downgraded: imprecision |
Infliximab versus placebo
Population: patients with active ulcerative colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Improved IBDQ at week 8 Infliximab vs placebo | RR 1.39 [1.21, 1.6] | 1 study · 728 participants | High |
IBDQ at week 6 or 8 Infliximab vs placebo | no estimate extracted | 2 studies · 529 participants | High |
EQ‐5D at week 6 Infliximab vs placebo | no estimate extracted | 1 study · 43 participants | Low Downgraded: imprecision |
Improved SF‐36 PCS at week 8 Infliximab vs placebo | RR 1.51 [1.23, 1.85] | 1 study · 728 participants | Moderate Downgraded: imprecision |
Improved SF‐36 MCS at week 8 Infliximab vs placebo | RR 1.44 [1.16, 1.79] | 1 study · 728 participants | Moderate Downgraded: imprecision |
Adalimumab versus placebo
Population: patients with active ulcerative colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Improved IBDQ at week 8 Adalimumab vs placebo | RR 1.23 [1.06, 1.43] | 2 studies · 767 participants | Moderate Downgraded: imprecision |
Improved IBDQ at week 52 Adalimumab vs placebo | RR 1.73 [1.28, 2.34] | 2 studies · 767 participants | Moderate Downgraded: imprecision |
IBDQ at week 8 Adalimumab vs placebo | no estimate extracted | 1 study · 494 participants | Moderate Downgraded: imprecision |
IBDQ at week 52 Adalimumab vs placebo | no estimate extracted | 1 study · 494 participants | Moderate Downgraded: imprecision |
Golimumab versus placebo
Population: patients with active ulcerative colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
IBDQ at week 6 Golimumab vs placebo | no estimate extracted | 1 study · 504 participants | High |
Vedolizumab versus placebo
Population: patients with active ulcerative colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Improved IBDQ at week 6 Vedolizumab vs placebo | RR 1.62 [1.15, 2.27] | 1 study · 374 participants | Moderate Downgraded: imprecision |
Improved IBDQ at week 52 Vedolizumab vs placebo | RR 1.67 [1.31, 2.12] | 1 study · 373 participants | Moderate Downgraded: imprecision |
SF‐36 PCS at week 6 Vedolizumab vs placebo | no estimate extracted | 1 study · 374 participants | Moderate Downgraded: imprecision |
SF‐36 MCS at week 6 Vedolizumab vs placebo | no estimate extracted | 1 study · 374 participants | Moderate Downgraded: imprecision |
SF‐36 PCS at week 52 Vedolizumab vs placebo | no estimate extracted | 1 study · 248 participants | Moderate Downgraded: imprecision |
SF‐36 MCS at week 52 Vedolizumab vs placebo | no estimate extracted | 1 study · 248 participants | Moderate Downgraded: imprecision |
TNF‐alpha antagonists versus placebo
Population: patients with active ulcerative colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Improved IBDQ at weeks 6 or 8 TNF‐alpha antagonists vs placebo | RR 1.32 [1.19, 1.46] | 3 studies · 1495 participants | High |
IBDQ at weeks 6 or 8 TNF‐alpha antagonists vs placebo | no estimate extracted | 4 studies · 1565 participants | Moderate Downgraded: inconsistency |